On August 31, 2026, BridgeBio Pharma entered into a voluntary agreement with the U.S. government to expand Medicaid access for its medicine Attruby via the GENEROUS Model and lower drug costs for American patients. The company expects this arrangement to exclude future pricing mandates for medicines approved exclusively for orphan indications. Specific financial terms remain confidential. BridgeBio operates in the biopharmaceutical industry, developing and commercializing transformative medicines for rare genetic conditions.
